598 related articles for article (PubMed ID: 27197529)
21. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
22. Clonal evolution of acute myeloid leukemia highlighted by latest genome sequencing studies.
Zhang X; Lv D; Zhang Y; Liu Q; Li Z
Oncotarget; 2016 Sep; 7(36):58586-58594. PubMed ID: 27474172
[TBL] [Abstract][Full Text] [Related]
23. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia.
Levine RL; Valk PJM
Haematologica; 2019 May; 104(5):868-871. PubMed ID: 30923100
[No Abstract] [Full Text] [Related]
25. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
26. Single-cell whole exome and targeted sequencing in NPM1/FLT3 positive pediatric acute myeloid leukemia.
Walter C; Pozzorini C; Reinhardt K; Geffers R; Xu Z; Reinhardt D; von Neuhoff N; Hanenberg H
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29090521
[TBL] [Abstract][Full Text] [Related]
27. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.
Bibault JE; Figeac M; Hélevaut N; Rodriguez C; Quief S; Sebda S; Renneville A; Nibourel O; Rousselot P; Gruson B; Dombret H; Castaigne S; Preudhomme C
Oncotarget; 2015 Sep; 6(26):22812-21. PubMed ID: 26078355
[TBL] [Abstract][Full Text] [Related]
28. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
[TBL] [Abstract][Full Text] [Related]
29. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
Delsing Malmberg E; Johansson Alm S; Nicklasson M; Lazarevic V; Ståhlman S; Samuelsson T; Lenhoff S; Asp J; Ehinger M; Palmqvist L; Brune M; Fogelstrand L
Leuk Lymphoma; 2019 Feb; 60(2):409-417. PubMed ID: 30068244
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
Kayser S; Walter RB; Stock W; Schlenk RF
Curr Hematol Malig Rep; 2015 Jun; 10(2):132-44. PubMed ID: 25994952
[TBL] [Abstract][Full Text] [Related]
32. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
[TBL] [Abstract][Full Text] [Related]
33. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
[TBL] [Abstract][Full Text] [Related]
35. Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes.
Waalkes A; Penewit K; Wood BL; Wu D; Salipante SJ
Haematologica; 2017 Sep; 102(9):1549-1557. PubMed ID: 28572161
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing.
Mack EKM; Marquardt A; Langer D; Ross P; Ultsch A; Kiehl MG; Mack HID; Haferlach T; Neubauer A; Brendel C
Haematologica; 2019 Feb; 104(2):277-287. PubMed ID: 30190345
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
38. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
Behdad A; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2015 Jan; 17(1):76-84. PubMed ID: 25468431
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of
Ferret Y; Boissel N; Helevaut N; Madic J; Nibourel O; Marceau-Renaut A; Bucci M; Geffroy S; Celli-Lebras K; Castaigne S; Thomas X; Terré C; Dombret H; Preudhomme C; Renneville A
Haematologica; 2018 May; 103(5):822-829. PubMed ID: 29472349
[TBL] [Abstract][Full Text] [Related]
40. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
